Davis Anne R, Saadatmand Heva J, Pack Alison
Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York, U.S.A.
Columbia University College of Physicians and Surgeons, New York, New York, U.S.A.
Epilepsia. 2016 Nov;57(11):1843-1848. doi: 10.1111/epi.13559. Epub 2016 Sep 28.
Effective contraception enables women with epilepsy (WWE) to plan their pregnancies and improve outcomes for themselves and their children. Although popular among all women, complex drug interactions limit the efficacy and safety of oral contraceptives (OCs) for WWE. We sought to explore the safety, acceptability, and pharmacokinetic impact of a progestin-containing intrauterine device (IUD) in WWE.
We enrolled 20 women with well-controlled epilepsy and a stable antiepileptic drug (AED) regimen and who were initiating a progestin-containing IUD (levonorgestrel 52 mg) in a prospective, observational study. For each AED, we compared the trough concentration before IUD insertion to the trough concentration 3 weeks, and 3 and 6 months later. Participants recorded seizures in a daily paper diary. We compared seizures that occurred during the month before IUD insertion to those occurring in the 6 months thereafter. Participants completed an acceptability questionnaire at 3 and 6 months.
Participants' average age was 28 years; 60% were nulligravid. They reported a history of multiple seizure types. During the baseline month, 75% were seizure-free and the remainder reported between one and three seizures. Fourteen received monotherapy and six received polytherapy. Lamotrigine use was most common (n = 12). AED trough concentrations remained stable during the 6 months after IUD insertion, without clinically meaningful deviations from baseline. Diary data showed that seizure frequency worsened in 3, and remained unchanged in 13 and improved in 4 after IUD insertion. Subjectively, no participant believed the IUD worsened her seizure control. All participants were either somewhat or very satisfied with the IUD throughout the study. All participants continued the IUD use at 6 months. No pregnancies occurred.
This pilot study suggests that the progestin-containing IUD is a safe and acceptable long-acting contraceptive for WWE.
有效的避孕措施能使癫痫女性(WWE)规划其妊娠,并改善她们自身及子女的结局。口服避孕药(OCs)虽在所有女性中都很常用,但复杂的药物相互作用限制了其对WWE的有效性和安全性。我们试图探讨含孕激素宫内节育器(IUD)在WWE中的安全性、可接受性及药代动力学影响。
我们纳入了20名癫痫得到良好控制且抗癫痫药物(AED)治疗方案稳定的女性,她们在一项前瞻性观察性研究中开始使用含孕激素的宫内节育器(左炔诺孕酮52 mg)。对于每种AED,我们比较了宫内节育器插入前的谷浓度与3周后、3个月和6个月后的谷浓度。参与者在纸质日记中记录癫痫发作情况。我们比较了宫内节育器插入前1个月内发生的癫痫发作与此后6个月内发生的癫痫发作。参与者在3个月和6个月时完成一份可接受性问卷。
参与者的平均年龄为28岁;60%为未孕。她们报告有多种癫痫发作类型的病史。在基线月份,75%的人无癫痫发作,其余人报告有1至3次癫痫发作。14人接受单药治疗,6人接受联合治疗。最常用的AED是拉莫三嗪(n = 12)。宫内节育器插入后的6个月内,AED谷浓度保持稳定,与基线相比无临床意义上的偏差。日记数据显示,宫内节育器插入后,3人的癫痫发作频率恶化,13人保持不变,4人有所改善。主观上,没有参与者认为宫内节育器会使她的癫痫控制恶化。在整个研究过程中,所有参与者对宫内节育器都有些或非常满意。所有参与者在6个月时都继续使用宫内节育器。没有妊娠发生。
这项初步研究表明,含孕激素的宫内节育器对WWE是一种安全且可接受的长效避孕方法。